ARTICLE SUMMARY:
DexCom is a dominant force in the continuous glucose monitoring (CGM) market, but the company is not about to rest on its laurels. The MedTech Strategist recently spoke at length with DexCom CEO Kevin Sayer about the challenges of breaking down longstanding barriers to CGM access and adoption, and what the future might bring for this industry.
Founded in 1999, diabetes device pure-play DexCom Inc. has grown into a powerhouse in the continuous glucose monitoring (CGM) arena.
